Evogliptin
CAS: 1222102-29-5
Ref. 3D-XYB10229
| 1mg | Descatalogado | ||
| 2mg | Descatalogado | ||
| 5mg | Descatalogado | ||
| 10mg | Descatalogado | ||
| 25mg | Descatalogado |
Información del producto
Nombre:
Evogliptin
Sinónimos:
- 2-Piperazinone, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(1,1-dimethylethoxy)methyl]-, (3R)-
- DA 1229
- (3R)-4-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(1,1-dimethylethoxy)methyl]-2-piperazinone
Descripción:
Evogliptin is an oral anti-diabetic drug that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is a potent inhibitor of P-glycoprotein, which may affect its absorption, distribution, metabolism and excretion. Evogliptin has been shown to reduce the risk of congestive heart failure in patients with type 2 diabetes mellitus by reducing inflammation and oxidative stress. The pharmacokinetics of evogliptin have been studied in vitro using human macrophages and in vivo using healthy volunteers and patients with type 2 diabetes mellitus. Evogliptin also reduces hepatic steatosis and hepatic impairment as well as human macrophages.
Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:
Propiedades químicas
Peso molecular:
401.4 g/mol
Fórmula:
C19H26F3N3O3
Pureza:
Min. 95%
MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:
